VT6.F Voyager Therapeutics Inc

Healthcare Biotechnology Frankfurt Exchange
1.46 EUR
Close of Nov 13, 2026
1.47 4.38
Market cap
EUR 91.0M
P/E
-
P/B
0.81x
ROE
-76.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is VT6.F undervalued?

Graham number

The Graham number of Voyager Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Voyager Therapeutics Inc fundamental analysis

No fundamental analysis for Voyager Therapeutics Inc yet.

Voyager Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to targ…

Full company profile